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Background: Individual trials are often underpowered to show differences in rare
adverse clinical events such as very late stent thrombosis (VLST; after one-year,
definite + probable ST). The RESOLUTE clinical program comprises 5 trials
prospectively designed with similar definitions, and adjudication procedures, that
allows pooled analysis of clinical endpoints.
Methods: Over 5,000 patients treated with the Resolute zotarolimus-eluting stent (R-
ZES) were pooled from the RESOLUTE All Comers randomized trial, comparing
R-ZES (N = 1140; 2 yr follow-up) with the XIENCE V everolimus-eluting stent (EES,
N=1152) and 4 single-arm studies: the RESOLUTE first-in-human (N = 139; R-FIM,
4 yr follow-up); the open label RESOLUTE International (N=2349; R-Int, 1 yr follow-
up); RESOLUTE Japan (N=100; 1 yr follow-up); and RESOLUTE US (N=1402; 1 yr
follow-up). Pooled safety endpoints (cardiac death, myocardial infarction [MI], and
VLST) for R-ZES patients were compared with EES patients from Resolute All
Comers. Pooled outcomes of single-vessel treated R-ZES patients (N = 2466) were
compared with BMS-treated patients (N = 596) from the ENDEAVOR II randomized
trial. RESOLUTE trials recommended six months dual antiplatelet therapy (DAPT);
ENDEAVOR II patients received 12 weeks of DAPT. Propensity scores were used to
adjust for differences in patient characteristics.
Results: At two years, the cumulative frequency of ST was 1.0% for R-ZES and EES
(adjusted hazard ratio 1.335; p=0.424) and VLST was 0.2% for R-ZES and 0.3% for
EES (adjusted hazard ratio 0.908; p=0.906). The cumulative ST rate for the single-
lesion R-ZES subset was 0.3% and for the BMS group was 1.3% (adjusted hazard ratio
0.026, p=0.0125). The cumulative incidence of cardiac death or MI was similar for all
the groups (R-ZES 5.4%, EES 6.2%, R-ZES subset 4.3%, BMS 5.8%; p=ns for both).
Conclusion: Pooled data analysis confirms a low rate of ST and VLST up to 2 years
for R-ZES. Cardiac death or MI in patients treated with R-ZES through 2 years was
similar to EES. Further analysis of data with longer follow-up (2 yr follow up of R-
Int; 5 yr follow-up of R-FIM) will be presented.
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Background: Current guidelines recommend standard doses of aspirin and clopidogrel
following PCI. However, clinical studies show heterogeneity in responses to
antiplatelet therapy (APT) and high residual platelet reactivity is associated with
increased risk of adverse events, including stent thrombosis (ST). Individualized
assessment of response to APT has not been widely implemented largely due to lack
of a standardized and generally accepted platelet function test (PFT) appropriate for
routine clinical use. We investigated the prevalence of APT hyporesponsiveness in ST
and whether APT efficacy can be optimised with tailored therapy.
Methods: Between October 2009 and June 2011, 39 patients were admitted to our
institution with definite ST. Response to aspirin and clopidogrel was measured
following discharge using Short Thrombelastography (s-TEG), a simple, rapid and
reproducible PFT that has been developed and validated by this group. Changes to
APT were directed by s-TEG in hyporesponders and repeat testing undertaken
following treatment modification.
Results: Median time from index PCI to ST was 1125 days. At presentation, 2 (5%)
patients were on no APT (non-compliance), 11 (28%) were on both aspirin and
clopidogrel, 1 (3%) was on clopidogrel alone and 25 (64%) were on aspirin alone. s-
TEG testing showed that 12 (31%) patients had an adequate response to both aspirin
and clopidogrel, 16 (41%) were hyporesponsive to clopidogrel alone, 1 (3%) was
hyporesponsive to aspirin alone and 10 (26%) were hyporesponsive to both aspirin
and clopidogrel. Treatment modification in hyporesponders included an increase in
aspirin dose and/or changing clopidogrel to prasugrel. 3 patients who were
hyporesponsive to both clopidogrel and prasugrel were switched to ticagrelor. Out of
the 22 patients so far who have been retested following treatment modification, an
adequate response to APT has been achieved in 19 (86%). None have presented with
a further ST episode.
Conclusion: There is a high prevalence of hyporesponsiveness (69%) to aspirin and/or
clopidogrel in patients with ST. Improved APT efficacy can be achieved by tailored
therapy. s-TEG is a plausible PFT that can be used to deliver point-of-care personalized
APT. Further data are required to investigate the possibility of dynamic changes in
responses to APT and to determine whether tailored therapy leads to improved long
term clinical outcomes.
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Background: In light of the possible safety concerns from usage of drug-eluting stents
in complex populations, determining whether differences exist between on-label
(standard risk) or off-label (extended risk) use is important. Little is known in this
regard with second generation stents.
Methods: Using all available data, we analyzed 13,259 patients (7,841 on- and 5,418
off-label) receiving XIENCE V everolimus-eluting coronary stent systems (Abbott
Vascular, Santa Clara, CA) from 7 studies (3 pre-approval [SPIRIT II, III, IV] and 4
post-marketing [SPIRIT V and SPIRIT Women, XIENCE V USA, XIENCE V India]).
Definite/probable ST was adjudicated per Academic Research Consortium definition
by an independent clinical events committee.
Results: The 2-year cumulative ST rate in all patients receiving XIENCE V was 0.74%.
Dual antiplatelet therapy compliance and ST rates up to 730 days are shown in the
Table.
Conclusion: In this large, patient-level pooled safety analysis, the 2-year cumulative
ST rate in all patients receiving XIENCE V was 0.74% and was higher in the first year
with off-label use (0.39% on-label vs. 0.95% off-label). ST was uncommon after year
1 with everolimus-eluting stents (~0.1%) irrespective of on- or off-label usage.
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Background: Dual antiplatelet therapy (DAPT) interruption prior to 180 days (d) with
first generation DES is associated with a higher risk of stent thrombosis (ST). We
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sought to examine the risk of subsequent ST associated with any DAPT interruption
(aspirin or thienopyridine) with XIENCE V everolimus-eluting coronary stent systems
(EES) (Abbott Vascular, Santa Clara, CA) in 13,259 patients from 7 studies (3 pre-
approval [SPIRIT II, III, IV] and 4 post-marketing [SPIRIT V and SPIRIT Women,
XIENCE V USA, XIENCE V India].
Methods: Definite/probable ST was adjudicated per ARC definition by an independent
clinical events committee. Analyses were conducted to assess overall ST rates and the
relationship between first DAPT interruption and subsequent ST.
Results: 2-year follow-up was complete in 12,552 pts, of whom ST occurred in 93 pts
(0.74%). By Kaplan-Meier analysis the 2-year ST rate was 0.71%. ST rates landmarked
sequentially from 30, 90, 180 and 365 d were 0.34%, 0.06%, 0.07%, 0.14%,
respectively. DAPT interruption data at different time intervals appears in the Table.
Conclusion: In this analysis of 13,259 patients receiving EES in a broad cross-section
of geographies, patients and lesions, 2-year cumulative ST rates were 0.74%. DAPT
interruption before 30 days was strongly associated with increased ST. Conversely, ST
rates were not increased with DAPT discontinuation after 30 days in patients who
received EES.
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Background: There are limited data about differences in outcome after stent
thrombosis (ST) according to the timing of the event.
Methods: A total of 3,602 pts with ST-segment elevation myocardial infarction
(STEMI) treated with primary percutaneous coronary intervention (PCI) were included
in HORIZONS-AMI. Stents were implanted in 3,202 pts. During 3-year follow-up
ARC-defined definite/probable ST occurred in 156 pts (4.9%). We compared 1-year
clinical outcomes after ST according to the timing of the event; acute (<24 hours),
subacute (24 hours-30 days), late (30 days-1 year), and very late (1 year-3 years).
Results: Acute ST occurred in 28 pts (18%), subacute ST in 48 pts (31%), late ST in
30 pts (19%), and very late ST in 50 pts (32%). One year mortality is shown in Figure
1. Subacute ST had the highest 1-year mortality (39.7%) while mortality for other ST
types was <10%. Most deaths occurred within the first weeks after the ST event. Rates
of reinfarction were higher in patients with late (77.1%) and very late ST (86.0%)
compared with acute (57.1%) and subacute ST (59.3%, p for trend <0.01). The
composite endpoint of death/reinfarction occurred with similar frequency in all ST
types (acute 64.3%, subacute, 83.3%, late 80.0%, very late 86.0%, p for trend
0.13).Major bleeding was more frequent in patients with acute (26.8%) and subacute
ST (13.6%) compared with late (3.7%) and very late ST (6.3%, p for trend 0.03).
Conclusion: This large cohort of patients with ST after primary PCI for STEMI
showed that mortality was highest after subacute ST. Reinfarction was less frequent,
and major bleeding was more frequent in patients with acute and subacute ST compared
with late and very late ST.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor
Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of
percutaneous coronary intervention in patients with diabetes mellitus (DM).
Methods: A prospective analysis of 2972 patients with DM (808 SES, 720 PES, 299
ECS, 404 ZES-R, 320 BES, 421 EES) in six high volume Asian centers after successful
stenting was performed. The study endpoints were 30 days major adverse cardiac
events (MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and
MACE.
Results: See table for clinical results.
www.JACC.TCTAbstracts2011
B24 JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/ORAL/Diabetes
O
R
A
L
S
